AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in ...

As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...

AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

AstraZeneca PLC on Monday said Enhertu reduced the risk of disease progression in a form of breast cancer. The Cambridge, England-based pharmaceutical company said Enhertu plus pertuzumab reduced the ...

Charities and campaigners said the new findings add to the 'betrayal' that they cannot get the life-extending drug on the NHS ...

Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

AstraZeneca and Daiichi Sankyo ... endocrine therapy in the metastatic setting. Enhertu is already approved for patients with HR+, HER2-low breast cancer after endocrine therapy based on the ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time, setting up regulatory filings.

Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing ...